Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 142

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 142
---
     | $         | 36.37 |
| New investors(1)      |     |                  | 16,666,667 |     |         |  83 | % |     |                     | 250,000,005 |     |         |  67 | % |     |           | 15.00 |
| Total                 |     |                  | 20,100,137 |     |         | 100 | % |     | $                   | 374,886,177 |     |         | 100 | % |     |           | 18.65 |

| (1) | The presentation in this table regarding ownership by existing stockholders does not give effect to any 
 purchases that existing stockholders may make in this offering.                                         |

Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors in this offering by $16.7 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. Similarly, each 1.0 million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all stockholders and the average price per share paid by all stockholders by $15.00 million, assuming the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting the underwriting discounts and commissions payable by us. The table above assumes no exercise of the underwriters’ option to purchase additional shares of common stock in this offering. If the underwriters were to fully exercise their option to purchase additional shares of common stock from us, the percentage of our common stock held by existing stockholders after this offering would be reduced to 17% of the total number of shares of our common stock outstanding after this offering, and the percentage of our common stock held by new investors would be increased to 83% of the total number of shares of our common stock outstanding after this offering. 94

The number of shares